The rapid advancements in the field of oncology have resulted in the transition from cytotoxic chemotherapeutic agents to molecularly targeted therapies that interfere with cellular signaling pathways important for the survival and propagation of neoplastic cells. Some of these agents have changed the landscape in the management of several hematologic and solid malignancies. Molecularly targeted agents are selected and designed to provide the maximal antitumor affect with the minimal functional alteration of the normal healthy cells. However, the complexity of cellular pathways proves very difficult to design therapeutic agents that do not overlap with the physiologic activities of the normal human tissues. The recognition of a myriad of distinct adverse effects related to the molecularly targeted therapies has emerged over the last decade with their increased clinical usage.
|Original language||English (US)|
|Title of host publication||Clinical Ophthalmic Oncology|
|Subtitle of host publication||Basic Principles and Diagnostic Techniques, Second Edition|
|Publisher||Springer Berlin Heidelberg|
|Number of pages||10|
|State||Published - Jan 1 2014|
ASJC Scopus subject areas